Form 4: Tarsus Pharmaceuticals Director Stock Options Granted

Andrew D. Goldberg, a Director at Tarsus Pharmaceuticals, Inc., received stock options and restricted stock units on June 25, 2026.

Summary

• Andrew D. Goldberg, a Director of Tarsus Pharmaceuticals, Inc., was granted stock options and Restricted Stock Units (RSUs) on June 25, 2026.
• The stock option is for 3,837 shares with an exercise price of $64.34 and an expiration date of June 24, 2036.
• The RSUs granted are for 2,417 shares.
• Both the stock options and RSUs are subject to vesting in full on the one-year anniversary of the grant date, contingent upon continuous service as a non-employee director.
• These grants were made in connection with Mr. Goldberg's service as a non-employee director as of the Company's 2026 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions related to director compensation rather than significant operational or financial news.

Positives

• Director compensation through equity awards (stock options and RSUs) indicates alignment of management interests with shareholders.
• The grant of options and RSUs suggests confidence in the company's future performance, as these awards are typically valued based on potential stock appreciation.
• Vesting schedules tied to continued service incentivize long-term commitment from directors.

Negatives

• The exercise price of the stock options ($64.34) is significantly higher than the current market price, implying that the options may not be immediately in-the-money.
• The filing does not provide details on the total compensation package for directors, making it difficult to assess the magnitude of these awards in context.

Risks

• The value of the stock options and RSUs is directly tied to the future performance of Tarsus Pharmaceuticals' stock price. A decline in stock price would diminish the value of these awards.
• The vesting condition of continuous service means that if the director's service is terminated before the vesting date, the awards will not vest.

Future Outlook

The future outlook for the value of the granted stock options and RSUs is dependent on the company's stock performance, with vesting contingent on continued service.

Industry Context

StockSavvy.ai notes that the granting of stock options and RSUs to directors is a common practice in the pharmaceutical industry to attract and retain experienced leadership and align their interests with long-term shareholder value.

Related Party Transactions

• Grant of stock options and Restricted Stock Units to Director Andrew D. Goldberg as part of his compensation for services.

Stakeholder Impact

• Shareholders: The issuance of equity awards dilutes existing share ownership, but also aligns director incentives with shareholder value creation.
• Employees: This filing does not directly impact employees, but reflects the company's compensation strategy for its board.
• Management: The filing details compensation for a key member of the board, reflecting standard corporate governance practices.

Next Steps

• Andrew D. Goldberg must maintain continuous service as a non-employee director for the stock options and RSUs to vest.
• The stock options can be exercised by the director on or after the vesting date until their expiration.

Key Dates

Keywords

Tarsus Pharmaceuticals, Form 4, Stock Options, Restricted Stock Units, Director Compensation, SEC Filing, Insider Trading, Equity Awards, Andrew D. Goldberg